Stem Cell Clinic

OncoMed to Present New Data in Six Anti-Cancer Stem Cell Programs at AACR

REDWOOD CITY, Calif.--(BUSINESS WIRE)--

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced an oral presentation and five posters that will highlight the progress of OncoMeds pipeline of anti-cancer biologics at the Annual Meeting of the American Association of Cancer Research in Washington D.C., April 7 9, 2013.

Oral Presentation, Sunday, April 7, 1:30 1:55 pm ET, Room 207, Washington Convention Center

As part of the New Drugs on the Horizon Special Session, Timothy Hoey, PhD, OncoMeds Senior Vice President of Cancer Biology, will discuss, Development of FZD8-Fc (OMP-54F28), a Wnt signaling antagonist that inhibits tumor growth and reduces tumor initiating cell frequency.

Poster #218, Sunday, April 7, 1 5 pm ET, Hall A-C, Poster Section 13

R-Spondin (RSPO) signaling drives the growth of multiple human tumor types will be presented by Austin Gurney, PhD, Senior Vice President of Molecular and Cellular Biology at OncoMed, in the Tumor Biology 2 Poster Session.

Poster #3725, Tuesday, April 9, 1 5 pm ET, Hall A-C, Poster Section 12

Anti-DLL4 (demcizumab) Inhibits tumor growth and reduces cancer stem cell frequency in patient-derived ovarian cancer xenografts will be presented by Wan-Ching Yen, PhD, Senior Scientist at OncoMed, in the Tumor Biology 35 Poster Session.

Poster #213, Sunday, April 7, 1- 5 pm ET, Hall A-C, Poster Section 13

Novel NOTCH3 activating mutations identified in tumors sensitive to OMP-59R5, a monoclonal antibody targeting the Notch2 and Notch3 receptors will be presented by Breanna Wallace, PhD, Post-Doctoral Research Fellow at OncoMed, in the Cancer Stem Targeting Therapies Poster Session.

Read more:
OncoMed to Present New Data in Six Anti-Cancer Stem Cell Programs at AACR

Dr. Doohi Lee introduces Stem Cell Therapy at Advanced Surgical Arts

Dr. Lee is one of the first in Texas to use adipose stem cell treatment to care for patients.

Plano, TX (PRWEB) April 03, 2013

Adipose tissue is fat inside the body. Fat is the richest source of adult stem cells in the human body. Stem cells help fight disease or injury by repairing or rejuvenating affected tissue in the body. Medical researchers believe that stem cell treatments have the potential to change the face of human disease.

In the procedure performed by Dr. Lee, fat will be extracted from the body, purified and re-injected into specific areas that need stem cells. Dr. Lee uses an automated machine called the Adivive Lipokit to perform the fat transplantation. The Adivive Lipokit is an all-in-one, FDA-approved device that collects, filters and transfers fat for use in cosmetic and reconstructive surgeries. The Lipokit is able to keep transferred fat cells alive throughout the process.

Procedures that will use adipose stem cell therapy include breast augmentation, facelift surgery, liposuction and fat transfer.

Besides cosmetic purposes, Dr. Lee will also use the Lipokit stem cell therapy for rejuvenation to help relieve chronic pain, whether from aging or due to injuries.

About the company

Advanced Surgical Arts was established in Plano, Texas in 2003. With three board certifications, Dr. Doohi Lee is able to offer his patients a multi-faceted approach to health and well-being. Continuing education is a priority for Dr. Lee, and he regularly attends seminars and conferences to expand his knowledge on cosmetic procedures and anti-aging. Dr. Lee constantly strives to investigate the latest and most minimally invasive procedures in cosmetic and laser vein surgery. His unified approach with artistry and technology provide patients at Advanced Surgical Arts with optimum results. For more information, please visit their website at http://advsurgicalartsdallas.com.

Maggie Gordon Advanced Surgical Arts Dallas 469-666-1075 Email Information

View post:
Dr. Doohi Lee introduces Stem Cell Therapy at Advanced Surgical Arts

Scientists develop new protocol to ready induced pluripotent stem cell clinical application

Apr. 3, 2013 A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors. Reported in PLOS ONE, this cell-sorting method consistently selects the highest quality, standardized iPS cells, representing a major step forward for drug discovery and the development of cell therapies.

Employing a breakthrough method developed by 2012 Nobel laureate Shinya Yamanaka, MD, PhD, adult cells are "reprogrammed" or reverted to an embryonic-like state, commonly through viral infection. Reprogramming is a dynamic process, resulting in a mixture of fully reprogrammed iPS cells, partially reprogrammed cells, and residual adult cells. Previous protocols to select promising fully reprogrammed cells rely primarily on judging stem cell colonies by eye through a microscope.

Cell colonies selected by qualitative measures could include partially reprogrammed cells, a major concern for clinical applications of cell therapies because these cells could become any other cell type in a patient following transplantation. Additionally for drug efficacy assays and toxicity investigations on iPS cells, heterogeneous cell populations can mar the response of representative iPS cell lines.

The NYSCF scientists developed a quantitative protocol, optimized over three and a half years, in order to consistently harvest early-reprogrammed cells. Using fluorescence activated cell sorting (FACS), fully reprogrammed cells were identified by two specific proteins, or pluripotency markers. The group then looked at third marker that is expressed by partially reprogrammed or adult cells, and they then negatively selected against these cells to obtain only fully reprogrammed cells.

"To date, this protocol has enabled our group to derive (and characterize over) 228 individual iPS cell lines, representing one of the largest collections derived in a single lab," said Dr. Kahler. "This standardized method means that these iPS cells can be compared to one another, an essential step for the use in drug screens and the development of cell therapies."

This process of selecting stem cell colonies provides the basis for a new technology developed by NYSCF, The NYSCF Global Stem Cell Array (Array), a fully automated, robotic platform to generate cell lines in parallel. Currently underway at the NYSCF Laboratory, the Array reprograms thousands of healthy donors' and diseased patients' skin and/or blood samples into iPS cell lines. Sorting and characterizing cells at an early stage of reprogramming allows efficient development of iPS cell clones and derivation of adult cell types.

"We are enthusiastic about the promise this protocol holds to the field. As stem cells move towards the clinic, Dr. Kahler's work is a critical step to ensure safe, effective treatments for everyone," said Susan L. Solomon, CEO of NYSCF.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

Go here to see the original:
Scientists develop new protocol to ready induced pluripotent stem cell clinical application

Part 19, after stem cell treatment, climbing up again and that’s good, 31march2013 – Video

Part 19, after stem cell treatment, climbing up again and that #39;s good, 31march2013
My name is Carole St-Laurent, I am from Rimouski, Quebec, Canada. I have a Spinal Muscular Atrophy from birth, it #39;s in the family of Muscular Dystrophy. I re...

By: Kina Diamond

View original post here:
Part 19, after stem cell treatment, climbing up again and that's good, 31march2013 - Video

Bioheart Completes FDA Registration for Tissue Bank Establishment

SUNRISE, FL--(Marketwired - Apr 2, 2013) - Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the FDA tissue bank registration process.Bioheart is offering stem cell storage for patients enrolled in the studies at the centers of excellence outside the US.Patients can store additional stem cell doses in liquid nitrogen for future use in approved clinical trials.These trials focus on the use of LipiCell (adipose derived stem cells) in a variety of different degenerative diseases.

Kristin Comella, Chief Science Officer, commented, "We are excited to offer these additional therapies to the patients who participate in our trials in Jamaica and Mexico.We now have the ability to store their stem cells for future use in repeat dosing studies."

About Bioheart, Inc.Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.

Follow this link:
Bioheart Completes FDA Registration for Tissue Bank Establishment

:: 02, Apr 2013 :: A*STAR HOSTS NOBEL LAUREATE AND RENOWNED STEM CELL EXPERT PROFESSOR SHINYA YAMANAKA

Nobel Laureate Professor Shinya Yamanaka to give a lecture on latest progress in stem cell research at Biopolis and share insights on stem cell research with A*STAR scientific leaders.

1. Professor Shinya Yamanaka, Nobel Laureate in Medicine or Physiology 2012, has been invited to speak at Biopolis under the A*STAR Biomedical Research Council Distinguished Visitor Programme (DVP). Professor Yamanakas discovery of induced pluripotent stem (iPS) cells in 2006, won him the Nobel Prize and revolutionised the stem cell field. Since then, iPS cells have been used to study cell therapy, disease mechanisms, and new drug developments worldwide. For Professor Yamanakas biography, please refer to Annex A.

2. Professor Yamanaka will be giving a scientific lecture today on the recent progress in induced pluripotent stem (iPS) cell research. Stem cells hold enormous potential in healthcare and medical sector as a renewable source of replacement tissues for regenerative medicine therapies. However, strict evaluation methods of selecting good iPS cell source for transplantation are essential to realise the promise of regenerative medicine. Professor Yamanaka will speak about the latest efforts to standardise iPS cells in clinical grade and to construct the basis of iPS cell stock. Details and an abstract of the lecture can be found in Annex B.

3. Stem cell research is one of the key focus areas in A*STARs biomedical research institutes and A*STAR scientific leaders and key clinical partners will also have the opportunity to meet with Professor Yamanaka to discuss his experience and views on stem cell research. A*STAR researchers have been making remarkable strides in the stem cell field, from basic research to provide insights into the regulatory networks that drive reprogramming of cells, to harnessing the power of stem cell-based research to target tumours and enhance healing. More details on some recent A*STAR discoveries and developments in stem cell research can be found at Annex C.

4. The DVP provides a platform for scientific leaders in Singapores BMS community to interact with renowned scientists worldwide and to foster collaborative links. Previous distinguished scientists hosted under the DVP include Professor Susumu Tonegawa in 2006 (Winner of the 1987 Nobel Prize in Physiology or Medicine), Professor David Naylor (President of University of Toronto), Professor Iain Mattaj (Director-General, European Molecular Biology Laboratory) and Professor Sir John Savill (then Chief Scientist for the Scottish Government Health Directorates, and Vice-Principal and Head of the College of Medicine & Veterinary Medicine, University of Edinburgh, and current Biomedical Sciences International Advisory Council member). Since the inception of the DVP in 2001, over 70 distinguished visitors have visited Singapore.

________________________________________________________________

AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)

Enclosed:

Annex A Professor Shinya Yamanakas biography

Original post:
:: 02, Apr 2013 :: A*STAR HOSTS NOBEL LAUREATE AND RENOWNED STEM CELL EXPERT PROFESSOR SHINYA YAMANAKA